What is 3T Biosciences?
3T Biosciences operates at the intersection of biotechnology and oncology, focusing on the development of next-generation therapies. The company's core mission is to overcome the limitations of existing cancer treatments by discovering and validating novel targets that were previously considered inaccessible. By utilizing a sophisticated discovery engine, 3T Biosciences aims to broaden the reach of immunotherapy, potentially transforming the standard of care for diverse patient populations. Their market position is defined by a commitment to precision medicine, where the identification of unique tumor-specific targets serves as the foundation for highly effective, targeted therapeutic interventions.
How much funding has 3T Biosciences raised?
3T Biosciences has raised a total of $40.1M across 2 funding rounds:
Debt
$150K
Series A
$40M
Debt (2020): $150K with participation from PPP
Series A (2022): $40M led by Lightspeed Venture Partners and Westlake Village BioPartners
Key Investors in 3T Biosciences
Lightspeed Venture Partners
A global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer, fintech, and infrastructure.
Westlake Village BioPartners
A life science venture capital firm focused on investing in world-class entrepreneurs to create innovative biotech companies that transform scientific breakthroughs into effective treatments.
PPP
Public-Private Partnership
What's next for 3T Biosciences?
With the recent capital influx, 3T Biosciences is expected to prioritize the expansion of its clinical pipeline and the scaling of its discovery platform. The company will likely focus on advancing its lead candidates through preclinical validation and into early-phase human trials. Furthermore, the strategic backing from top-tier life science investors suggests a roadmap that includes strengthening internal R&D capabilities and potentially pursuing collaborative partnerships to enhance the commercial viability of their therapeutic assets. As the firm matures, the focus will remain on translating scientific breakthroughs into scalable, life-saving treatments for patients suffering from solid tumors.
See full 3T Biosciences company page
